Not available
Quote | Lipocine Inc. (NASDAQ:LPCN)
Last: | $4.55 |
---|---|
Change Percent: | 0.45% |
Open: | $4.42 |
Close: | $4.55 |
High: | $4.6047 |
Low: | $4.41 |
Volume: | 7,965 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
News | Lipocine Inc. (NASDAQ:LPCN)
2024-04-12 08:32:45 ET More on Pre-market losers & stocks. Candel Therapeutics receives FDA orphan drug designation for its pancreatic cancer treatment Adial stock rallies 81% on data for alcohol abuse drug Seeking Alpha’s Quant Rating on Adial Pharmaceuti...
2024-04-11 09:01:37 ET DENVER, Colo., Apr 11, 2024 ( 247marketnews.com )- Lipocine Inc. (NASDAQ: LPCN ) results from a Phase 2 clinical trial including LPCN 2401, an oral proprietary combination of anabolic androgen receptor agonist and α-tocopherol, an antioxidant, which sho...
Message Board Posts | Lipocine Inc. (NASDAQ:LPCN)
Subject | By | Source | When |
---|---|---|---|
$LPCN short squeeze signal | RunninRobert | investorshub | 05/12/2023 7:26:37 AM |
Bottom was in on the eighth | Triple nickle | investorshub | 05/11/2023 4:27:09 PM |
Added | Triple nickle | investorshub | 05/11/2023 4:25:38 PM |
Time for this to show some returns | gi197845 | investorshub | 05/11/2023 4:04:56 AM |
$LPCN Found an interesting article | gi197845 | investorshub | 05/10/2023 6:49:32 PM |
News, Short Squeeze, Breakout and More Instantly...
2024-04-11 09:01:37 ET DENVER, Colo., Apr 11, 2024 ( 247marketnews.com )- Lipocine Inc. (NASDAQ: LPCN ) results from a Phase 2 clinical trial including LPCN 2401, an oral proprietary combination of anabolic androgen receptor agonist and α-tocopherol, an antioxidant, which sho...
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity PR Newswire LPCN 2401 treatment resulted in statistically significant body composition improvement in men Increased lean mass (LM) by 4.4% and decreased fa...
Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis PR Newswire Met primary and Hepatic Encephalopathy (HE) endpoints in Phase 2 study Increase in Skeletal Muscle Index (SMI) observed at Week 24 was maintained through 52...